To include your compound in the COVID-19 Resource Center, submit it here.

Lilly stretches Olumiant timeline, updates cancer strategy

Eli Lilly and Co. (NYSE:LLY) reported 2Q17 earnings and said it would delay its plans to resubmit an NDA for Olumiant baricitinib beyond 2017. The company also said it would narrow its oncology focus to prioritize a

Read the full 376 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE